Skip to main navigation
Skip to search
Skip to main content
HSC Home
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Search by expertise, name or affiliation
Pancreatic cancer: An emphasis on current perspectives in immunotherapy
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pancreatic cancer: An emphasis on current perspectives in immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pancreatic Cancer
100%
On-state Current
100%
Clinical Trials
50%
Cancer Patients
50%
Pembrolizumab
50%
Clinical Testing
33%
Survival Rate
33%
Immune System
16%
Tumor
16%
Malignancy
16%
T Cells
16%
Death Rate
16%
Treatment Effect
16%
Treatment Options
16%
Preclinical Research
16%
High Incidence
16%
Cancer Cells
16%
Metastasis
16%
Effective Strategies
16%
Difficult-to-treat
16%
Male Population
16%
Pancreatic Cancer Treatment
16%
Checkpoint Molecules
16%
Programmed Death-ligand 1 (PD-L1)
16%
Incidence Rate
16%
Metastatic Disease
16%
Advanced Disease
16%
Phase II Clinical Study
16%
Adoptive Cell Transfer
16%
Pelareorep
16%
Early Cancer
16%
Immune Checkpoint Inhibitors
16%
Reovirus
16%
Immunotherapeutic Approaches
16%
Cancer Immunotherapeutics
16%
Resectable Pancreatic Cancer
16%
Resistance to Chemotherapy
16%
Medicine and Dentistry
Immunotherapy
100%
Pancreas Cancer
100%
Clinical Trial
37%
Pembrolizumab
37%
Malignant Neoplasm
25%
Metastatic Carcinoma
25%
Survival Rate
25%
Immune System
12%
Disease
12%
Mortality Rate
12%
Side Effect
12%
Clinical Study
12%
Cancer
12%
T Cell
12%
Cancer Cell
12%
Neoplasm
12%
Cancer Therapy
12%
Treatment Effect
12%
Programmed Death 1 Receptor
12%
Cancer Staging
12%
Immune Checkpoint Inhibitor
12%
Reoviridae
12%
Pelareorep
12%
Transfer Cell
12%
Chemotherapy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Immunotherapy
100%
Malignant Neoplasm
37%
Clinical Trial
37%
Pembrolizumab
37%
Survival Rate
25%
Disease
12%
Side Effect
12%
Mortality Rate
12%
Neoplasm
12%
Metastasis
12%
Clinical Study
12%
Chemotherapy
12%
Programmed Death 1 Receptor
12%
Immune Checkpoint Inhibitor
12%
Pelareorep
12%
Reoviridae
12%
Cancer Staging
12%